

DOB:

ADUHELM[™] INDICATION CHECKLIST

This document is intended to help practitioners determine appropriateness of Aduhelm therapy, document clinical decision making, and support medical necessity. This guide is not intended to supersede guidance from the FDA, state/local licensing agencies, or other regulatory bodies. For complete information, refer to www.aduhelm.com

Criteria for Indications & Use			
 Diagnosis: G30.0 Alzheimer's disease, early onset G30.1 Alzheimer's disease, late onset G30.8 Other Alzheimer's disease G31.84 Mild cognitive impairment, so sta 	AND ← (G30.X codes require secondary F02.8X code) →		F02.80 Dementia without behavioral disturbance F02.81 Dementia with behavioral disturbance
2 Confirmation of Beta-Amyloid (Aβ) Pathology:			
Beta-amyloid PET scan	OR 🗆 (CSF	analysis
Date:	Dat	e:	
Result:	Res	ult:	
			(t-tau, p-tau, or p-tau:Aβ ratio)
(3) Confirmation of Cognitive Impairment:			
 General Practitioner Assessment of C Memory Impairment Screen (MIS) Result/Notes: 		er:	
Monitoring for Amyloid Related Imaging Abnormalities (ARIA)			
Recent brain MRI obtained prior to initiating therapy		۵	Date:
Result:		_	(within one year)
	negative	_	positive; see notes below
	 negative negative 		positive; see notes below positive; see notes below
Notes:		ш	positive, see notes below